

Express Mail No.: EQ 225 75 197 US
Attorney Docket No.: 011134-0077-999
CAM: 893053-999077

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Burkitt *et al.*
Serial No. : 10/666,857
Filed : September 19, 2003

Art Unit : 1626
Examiner : Anderson, Rebecca
Conf. No. : 5761

Title : Antiinflammation agents

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 AND 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

Copies of References B01-C22 are submitted herewith. References A01-A05 are U.S. patents. Therefore, copies of these references are not submitted herewith, pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(d), after the period specified in 37 C.F.R. § 1.97(c), but on or before payment of the issue fee.

The \$180.00 fee set forth in § 1.17(p) is to be charged to Jones Day Deposit Account No. 50-3013 (referencing 893053-999077). The Commissioner is authorized to change any additional fee, or credit any overpayment, to Jones Day Deposit Account No. 50-3013.

08/22/2006 GWORDOF1 00000078 503013 10666857
02 FC:1806 180.00 DA

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Serial No. 10/666,857

Attorney Docket No.: 011334-0077-999


CAM: 893053-999077

Page 2

No admission is made that the information cited in the attached List of References Cited by Applicant is, or is considered to be, material to patentability, nor that such references are available as "prior art" against the subject application.

Respectfully submitted,

Date: August 17, 2006



Megha Bhumralkar (Reg. No. 44,536)

JONES DAY

12750 High Bluff Drive, Suite 300

San Diego, CA 92130-2083

(858) 314-1180 – Direct

(858) 314-1150 – Fax

mbhumralkar@jonesday.com

For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

ainsogna@jonesday.com

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)ATTY. DOCKET NO.
11134-0077-999
(CAM 893053-999077)APPLICATION NO.
10/666,857APPLICANT
Burkitt, et al.FILING DATE
September 19, 2003GROUP
1626

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	US 3,845,065	10-29-1974	Shen et al.			
	A02	US 3,903,095	09-02-1975	Shen et al.			
	A03	US 6,649,654	02-08-2000	Mantlo et al.			
	A04	US 6,659,654	11-18-2003	Karin et al.			
	A05	US 6,022,884	02-08-2006	Mantlo et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 01/00610	01-04-2001					
	B02	WO 01/30774	03-05-2001					
	B03	WO 01/58890	08-16-2001					
	B04	WO 01/58899	08-16-2001					
	B05	WO 01/68648	09-20-2001					
	B06	WO 02/060386	08-08-2002					
	B07	WO 02/076985	10-03-2002					
	B08	WO 02/094265	11-28-2002					
	B09	WO 02/094322	11-28-2002					
	B10	WO 02/094813	11-28-2002					
	B11	WO 02/28860	04-11-2002					
	B12	WO 02/30353	04-18-2002					
	B13	WO 02/30423	04-18-2002					
	B14	WO 02/41843	05-30-2002					
	B15	WO 02/44153	06-06-2002					
	B16	WO 02/46171	06-13-2002					
	B17	WO 03/010158	02-06-2003					
	B18	WO 03/024935	03-27-2003					
	B19	WO 03/024936	03-27-2003					
	B20	WO 03/027075	04-03-2003					
	B21	WO 03/029242	04-10-2003					
	B22	WO 03/035625	05-01-2003					
	B23	WO 03/037886	05-08-2003					
	B24	WO 03/039545	05-15-2003					
	B25	WO 03/040131	05-15-2003					
	B26	WO 03/070706	08-28-2003					

	B27	WO 03/084959	11-16-2003					
	B28	WO 03/086309	10-23-2003					
	B29	WO 03/095430	11-20-2003					
	B30	WO 03/103648	12-18-2003					
	B31	WO 03/103658	12-18-2003					
	B32	WO 03/103661	12-18-2003					
	B33	WO 03/104218	12-18-2003					
	B34	WO 03/104219	12-18-2003					
	B35	WO 2004/009582	01-29-2004					
	B36	WO 95/02597	01-26-1995					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	ADHA, et al., "Synthesis of Complex Ethynyladenosines Using Organic Triflic Enolates in Palladium-Catalyzed Reactins: Potential Agonists for the Adenisone A ₂ Receptor" Tetrahedron, Vol. 53, No. 20; pp. 2747-6754, (1997)
	C02	BAICHWAL & BAEUERLE, "Apoptosis: Activate NF-KB or die?" Current Biology, 7:R94-R96 (1997)
	C03	COMINS, D. L. et al., "Lithiation of Heterocycles Directed by α -Amino Alkoxides" J. Org Chem. 52; pp. 104-109 (1987)
	C04	ELOY, F. and DERYCKERE, A., "Thienopyridines" Bulletin des Societes Chimiquet Belges; pp. 301-311 (1970) (English Abstract Provided at C05)
	C05	English Abstract of C04. ELOY, F., and DERYCKERE, A. "Thienopyridines" Bulletin des Societes chimiquet Belges" 79, 301-311 (1970)
	C06	GJOES et al., "Some Substitution Reactions of 2-Phenylthiophene" Acta Chemica Scandinavica, Vol. 26, No. 5, 1751-2162 (1972)
	C07	HEHNER, S.P. et al., "The anti-inflammatory sesquiterpene lactone parthenolide inhibits NV-kB by targeting the Ikb kinase complex", J. Immunol., Vol. 163; pp. 5617-5623 (1999)
	C08	JUNEK, H., et al., "Synthesen von Alkyl-bzw. Cycloalkylpyridinen und Naphthyridinen, " <u>Monatshefte fuer Chemie</u> ; Vol. 108, No. 3; pp. 689-702 (1977) (English Abstract Provided at C9)
	C09	English Abstract of C08. JUNEK, H., et al., "Report on the chemistry of enamino ketones, part 13, Syntheses of alkyl-cycloalkylpyridines, and naphthyridines", Montashefte fuer chemie, Vol. 108, No. 3, pp. 689-702 (1977)
	C10	KARIN, J., "The beginning of the End: Ikb Kinase (Ikk) and NF-kB Activation", The Journal of Biological Chemistry, Vol. 274, No. 39, pp. 27339-27342, Issue of September 24, 1999
	C11	KOITZ, G. et al., "Condensation products of dimeric malononitrile derivatives with 2,4-diketones and their application for the synthesis of substituted 1,6-naphtyridines", Heterocycles, Vol. 20, No. 12; pp. 2405-2409 (1983)
	C12	MALININ, N. et al., "MAP3K-related kinase involved in NF-kB induction by TNF, CD95 and IL-1", Nature, Vol. 385, pp. 540-544 (1997)
	C13	MERCURIO, F., et al, "IKK-1 And IKK-2: Cytokine-Activated Ikb Kinases Essential for NF-kB Activation", Science, Vol. 278; pp. 1054-1068 (1997)
	C14	POIRIER, Y. et al, "Composes sulfures heterocycliques. Xx(*) - Sulfuration d'alcoylidene cyclopentanones" Bulletin de la Societe Chimique de France; pp. 1054-1068 (1966) (English Abstract Provided at C15)
	C15	English Abstract of C14. POIRIER, Y. et al, "Heterocyclic sulfur compounds. xx. Sulfuration of alkylidenecyclopentanones" Bulletin de la Societe Chimique de France; pp. 1052-1068 (1966)
	C16	SILBERG, A., et al., "Beitrag zum Studium der Thiazole, VIII" Chem. Ber , 97(6); pp 1684-1687, (1964) (English Abstract Provided at C17)
	C17	English Abstract of C16. SILBERG, A., et al., "Thiazoles. VIII. Phenylthiazolecarboxaldehydes" Chem. Ber , 97(6); pp. 1684-1687, (1964)
	C18	SILVERMAN, J. et al., "3840 In Vitro and in vivo activity of SPC-595, a novel cell cycle inhibitory cytotoxic in murine syngeneic and human xenograft tumor models" Presentation at the 95 th American Association for Cancer Research, March 27-31, 2004
	C19	SKORCZ, J. A., SUH, J.T.; Germershausen, R. L. J. Heterocyclic, Vol. 10; pp 249-253 (1973)
	C20	VERMA, et al., Genes & Development, Vol. 9, No. 22; pp. 2723-2872 (1995)
	C21	WORONICZ, J.D., et al., "1 κ B: NF-kB Activation and complex Formation with Ikb Kinase- α and NIK" Science, Vol 278; October 31, 1997
	C22	ZHANG, Y., Homfeldt, A.-B; Gronowitz, S.; Stalhandske C. "Pyridine-Substituted Hydroxythiophenes. III. Dimerization of 3-(2-Pyridyl)thiophen-2(SH)-one from Demethylation Reaction of 2-Methoxy-3-(2-pyridyl)thiophene. X-Ray Structure Determination of (\pm)-(3R*, 4S*)-3-(2-Pyridyl)-4-[2-oxo-3(1,2-dihydropyridin-2-ylidene)-2,3-dihydro-thiophen-5-yl]-4,5-dihydrothiophen-2(3H)-one" Acta Chemica Scand. Vol. 48; pp. 843-849 (1994)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	